Program

Keynote Session

7:00 p.m.-8:00 p.m.

Welcome and opening remarks
Anil K. Rustgi, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Colorectal cancer genomes and their implications for basic and applied research
Bert Vogelstein, Johns Hopkins University, Baltimore, MD

Welcome Reception

8:00 p.m.-9:30 p.m.

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 1: Intestinal Stem Cells

8:00 a.m.-10:00 a.m.

Targeting dormant drug-resistant cancer stem cells
Linheng Li, Stowers Institute for Medical Research, Kansas City, MO

In vitro analysis of intestinal stem cells
Calvin J. Kuo, Stanford University, Stanford, CA

Relationship of intestinal epithelial progenitor cells within the stem cell niche
Melissa Hirose Wong, Oregon Health and Science University, Portland, OR

* STAT3 as a novel cancer therapeutic target in colorectal cancer stem cells
Li Lin, Center for Childhood Cancer, The Research Institute at Nationwide Children’s Hospital, Columbus, OH

* TNIK is a protein kinase essential for Wnt signaling and colorectal cancer growth
Tesshi Yamada, National Cancer Center Research Institute, Tokyo, Japan

Break

10:00 a.m.-10:30 a.m.

Session 2: Regulation of the Genome

10:30 a.m.-12:30 p.m.

Dampening of TGFbeta responses by Myc-regulated microRNAs: Implications for colon cancer angiogenesis
Andrei Thomas-Tikhonenko, University of Pennsylvania, Philadelphia, PA

Mismatch repair and colorectal cancer: Understanding pathogenic variants using yeast as a model system
Alison Gammie, Princeton University, Princeton, NJ

Towards a unified systems biology of colorectal carcinoma
Bruce J. Aronow, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

microRNA binding site polymorphisms and their impact on cancer risk, tumor biology, and outcome
Joanne B. Weidhaas, Yale University School of Medicine, New Haven, CT

Poster Session A / Lunch

12:30 p.m.-2:30 p.m.

Session 3: Genetics of Susceptibility

2:30 p.m.-4:30 p.m.

Contribution by predisposing genes to the etiology, diagnosis, and prevention of colorectal cancer
Albert de la Chapelle, Ohio State University Comprehensive Cancer Center, Columbus, OH

DNA repair and susceptibility to colon cancer
Joanna L. Groden, Ohio State University College of Medicine, Columbus, OH

The interaction of environmental exposures, germline susceptibility, and somatic alterations on colorectal cancer risk and survival
Charles S. Fuchs, Dana-Farber Cancer Institute, Boston, MA

* A genetic model for early-onset breast and colon cancer in African-Americans
Phillip Buckhaults, Medical College of Georgia Cancer Center, Augusta, GA

* mir-21 causes resistance to 5-fluorouracil by inducing MSH2-MSH6 downregulation in colon cancer
Nicola Valeri, Ohio State University, Columbus, OH

Evening off / Dinner on own

4:30 p.m.-

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 4: Inflammation and Tumor Microenvironment

8:00 a.m.-10:00 a.m.

Inflammatory mechanisms in colon tumorigenesis
Michael Karin, University of California, San Diego, La Jolla, CA

Gastrointestinal cancer and the tumor microenvironment
Timothy C. Wang, Columbia University Medical Center, New York, NY

Inflammatory mediators and their role in the progression of colorectal cancer
Raymond N. DuBois, University of Texas MD Anderson Cancer Center, Houston, TX

* Polarity regulator Cdc42 in intestinal epithelium morphogenesis and tumorigenesis
Ryotaro Sakamori, Rutgers, The State University of New Jersey, Newark, NJ

* Discovery of autoantibody targets in colorectal cancer by using phage microarrays
Ignacio Casal, Centro de Investigaciones Biológicas, Madrid, Spain

Break

10:00 a.m.-10:30 a.m.

Session 5: Mouse Models of Intestinal Cancer

10:30 a.m.-12:30 p.m.

Suppression of colon cancer metastasis by Aes through inhibition of notch signaling
Makoto Mark Taketo, Kyoto University Graduate School of Medicine, Kyoto, Japan

Mechanisms of crypt fission
Thaddeus S. Stappenbeck, Washington University School of Medicine, St. Louis, MO

Host genetic factors controlling development of flat colonic adenomas
David W. Threadgill, North Carolina State University, Raleigh, NC

* From human cancer genome to flies: Multigenic models of metastatic colon cancer in drosophila
Erdem Bangi, Mount Sinai Medical Center, New York, NY

* The effect of vitamin D receptor activation on β-catenin-regulated transcripts in mice with colonic inactivation of both APC alleles
Marsha DeSmet, Purdue University, West Lafayette, IN

Mentoring Groups / Lunch on own

12:30 p.m.-2:30 p.m.

Session 6: Advances in Diagnostics

2:30 p.m.-4:30 p.m.

Genetic opportunities for preventing death from colon cancer
Sanford D. Markowitz, Case Western Reserve University, Cleveland, OH

Early detection of colorectal cancer using stool DNA: Is it ready for prime time?
Nita Ahuja, Johns Hopkins Medical Institutes, Baltimore, MD

DNA methylation markers: Implications for therapy?
Stephen B. Baylin, Johns Hopkins School of Medicine, Baltimore, MD

* Next-generation stool DNA testing for detection of colorectal neoplasia: Early marker evaluation
David A. Ahlquist, Mayo Clinic, Rochester, MN

* The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits tumor growth in a genetically engineered mouse model for sporadic colon cancer
Kenneth E. Hung, Tufts Medical Center, Boston, MA

Poster Session B / Reception

5:00 p.m.-7:00 p.m.

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 7: Imaging of the GI Tract

8:00 a.m.-10:00 a.m.

Molecular imaging approaches to colorectal cancer
Umar Mahmood, Massachusetts General Hospital, Boston, MA

Miniaturized confocal microscope for early detection of GI cancers
Christopher H. Contag, Stanford University School of Medicine, Stanford, CA

Imaging colon cancer targets for therapy
Wafik S. El-Deiry, University of Pennsylvania School of Medicine, Philadelphia, PA

* Whole genomic sequencing of nine colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion
Adam Bass, Dana-Farber Cancer Institute, Boston, MA

* Genome-wide molecular and functional analysis identified LNX2 as a novel candidate gene involved in colorectal carcinogenesis
Jordi Camps, National Cancer Institute, Bethesda, MD

Break

10:00 a.m.-10:30 a.m.

Session 8: Clinical Trials and Experimental Therapeutics

10:30 a.m.-12:30 p.m.

Novel agents in early development for colorectal cancer: Approach to individualized therapy
S. Gail Eckhardt, University of Colorado Denver School of Medicine, Denver, CO

Managing the interface between chemotherapy and targeted therapy in patients with colorectal cancer
Richard M. Goldberg, University of North Carolina, Chapel Hill, NC

Efficacy and toxicity of VEGF inhibitors: Predictive markers and biological insights
Herbert I. Hurwitz, Duke University, Durham, NC

* An unappreciated role for EGFR-RasGEF signals in colorectal cancer with oncogenic K-RasG12V?
Philippe Depeille, University of California, San Francisco, CA

* Synergistic killing of colorectal cancer cells by oxaliplatin and the BH3-mimetic ABT-737 requires induction of noxa by wild-type p53 and oncogenic KRAS
Onno Kranenburg, University Medical Centre Utrecht, Utrecht, The Netherlands

Departure